Skip to main content
Premium Trial:

Request an Annual Quote

William Matthews, Constantine Anagnostopoulos, Richard Hawkins, Michael Sember, Andre Marion, Carol Reed, Gregory Sullivan

Premium

Four weeks after announcing that its president had left, Deltagen said Feb. 13 that its CEO, William Matthews, had resigned.

Matthews, a co-founder of Deltagen, has served as CEO since 1998. The office of board chairman, Constantine Anagnostopoulos, will manage the company until it finds a new CEO, Deltagen said.

The firm has been publicly searching for a new chief since November, but Matthews was co-directing day-to-day operations with Anagnostopoulos and CFO Richard Hawkins.

Matthews’ departure is the latest sign that the transgenic technology company, like others in the sector, has been struggling. On Jan. 21, President and COO Michael Sember left. At the time, the company had reduced its headcount to 200 and made plans to cut loose its proteomics subsidiary and its R&D center based in Strasbourg, France.

One month earlier the company received a warning letter from the Nasdaq exchange saying its stock is due to delist March 19 if shares continue to trade below $1.


ParAllele BioScience has appointed to its board of directors Applied Biosystems co-founder Andre Marion, the company said Feb. 11.

Marion served as chairman, CEO, and president of ABI for several years until the company’s merger with Perkin Elmer. He held various R&D management positions with Hewlett-Packard. Marion currently serves as a director on the boards of Aclara BioSciences, Molecular Devices, Cygnus, and Applied Imaging.


Genaissance Pharmaceuticals has promoted Carol Reed to vice president of medical affairs from her previous position of executive director of the department, the company said Feb. 14.

Reed, 49, came to Genaissance from Bayer Pharmaceuticals where she was an associate medical director in pulmonary medical research. Previously, Reed was associate director of pulmonary and critical-care medicine at the Hospital of St. Raphael, in New Haven, Conn., and director of its medical ICU.


Genomics Collaborative has named Gregory Sullivan director of business development and sales. Sullivan will be responsible for sales of the company’s Access program, and he will help develop partnerships with equipment vendors.

Before joining GCI, Sullivan was a principal in a specialized marketing consulting firm whose clients included Clifton Cardiology Center, in New Jersey; International Center for Aging Research, in Barcelona, Spain; and FMN International, in Washington.

Sullivan graduated from Columbia Business School with an MBA in strategic management and finance. Before that he received a PhD in molecular pharmacology from the Robert Wood Johnson Medical School and Rutgers University at The Cancer Institute of New Jersey.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.